Immunocore reports cash, equivalents of $820M as of December 31

More on Immunocore

• Immunocore Is Adequately Valued, But Its Prospects Are Uncertain
• Immunocore appoints Travis Coy as CFO
• Morgan St...

  Seeking Alpha | January 10, 2025

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma indications – potential data readouts beginning with TEBE-AM in 2026 Enrolling Phase 1/2 trial with brenetafusp combinations in ovarian and lung cancer; ongoing dose escalation with IMC-R117C (PIWIL1) and IMC-P115C (PRAME-A02-HLE) Presenting initial HIV Phase 1 MAD data in the first quarter 2025 Progressing

Yahoo | January 10, 2025

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in in a p

Yahoo | January 6, 2025

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune dis

Yahoo | January 2, 2025

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) targets the same peptide and has the same CD3 effector and TCR specificity as brenetafusp, and is designed with extended half-life The Phase 1 trial will assess the safety and clinical activity of IMC-P115C in HLA-A*02:01-positive patients with advanced solid tumors that express PRAME (OXFORDSHIRE, England & C

Yahoo | December 23, 2024

Immunocore doses first subject in gastrointestinal cancer therapy trial

The therapy is the fifth ImmTAC molecule from the company to enter clinical trials.

Yahoo | December 18, 2024

Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First immunotherapy program to target PIWIL1, a cancer-testis antigen overexpressed in a range of cancers, including colorectal cancer (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 17 December 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage

Yahoo | December 17, 2024

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh

Yahoo | December 13, 2024

All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy

Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Yahoo | December 12, 2024

Immunocore, EORTC announce enrollment of first patient in Phase 3 ATOM trial

The European Organisation for Research and Treatment of Cancer and Immunocore (IMCR) Holdings announced the randomization of the first patient in the Phase 3 Adjuvant Trial in Ocular Melanoma, investigating the safety and efficacy of tebentafusp as adjuvant treatment for uveal melanoma. The primary objective of the open-label, international, multicenter trial – led by EORTC – will be to assess whether tebentafusp can prevent or delay relapse in patients with primary ocular melanoma at high risk

Yahoo | December 12, 2024